Attana has received an order for contract research from a market leading biotech company.
Attana has received an order for contract research from a market leading biotech company. The order is a result of one of the company’s academic collaborations and will be carried out in collaboration with the academic group. The research will be performed with Attana’s patented biosensor technology for characterization of the interaction between cells and therapeutics.
The biotech company has a market leading drug and to maintain that position they now invest in RnD for the next generation of the drug.
Attana’s application specialists will perform experiments where the interaction between a specific receptor in the cell membrane of the target cells and a panel of potential drug candidates will be characterized in terms of interaction kinetics and affinity.
The work will be performed and invoiced during Q2.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com
tel: + 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact sales@attana.com.
Tags:
